Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
45   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine has presented as invited speaker at GBC 2018 on June 26-29, 2018   Admin   2019-01-14   426  
44   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited as a chairman of the session of the antibody therapeutics at BIOPLUS 2018 on September 6-9, 2018.   Admin   2019-01-14   443  
43   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a presentation as a speaker and panelist at AFOB SUMMER FORUM 2018   Admin   2019-01-14   435  
42   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is attending ASCO 2018.   Admin   2019-01-14   2,443  
41   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are attending BIO 2018.   Admin   2019-01-14   439  
40   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the company presentation session at BIO 2018.   Admin   2019-01-14   419  
39   PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.   Admin   2019-01-14   408  
38   `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.   Admin   2019-01-14   569  
37   ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed.   Admin   2019-01-14   439  
36   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018.   Admin   2019-01-14   408